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Recent studies suggest a powerful prognostic value for plasma
cytokine levels in primary myeloﬁbrosis (interleukin (IL)-2R,
IL-8, IL-12, IL-15 and C–X–C motif chemokine 10 (CXCL10)) and
large-cell lymphoma (IL-2R, IL-8, IL-10, IL-12, CXCL9 and
CXCL10). To examine the possibility of a similar phenomenon
in myelodysplastic syndromes (MDS), we used multiplex
enzyme-linked immunosorbent assay to measure 30 plasma
cytokines in 78 patients with primary MDS. Compared with
normal controls (n¼35), the levels of 19 cytokines were
signiﬁcantly altered. Multivariable analysis identiﬁed increased
levels of CXCL10 (Po0.01), IL-7 (P¼0.02) and IL-6 (P¼0.07) as
predictors of shortened survival; the survival association
remained signiﬁcant when the Cox model was adjusted for
the International Prognostic Scoring System, age, transfusion-
need or thrombocytopenia. MDS patients with normal plasma
levels of CXCL10, IL-7 and IL-6 lived signiﬁcantly longer
(median survival 76 months) than those with elevated levels
of at least one of the three cytokines (median survival 25
months) (Po0.01). Increased levels of IL-6 were associated with
inferior leukemia-free survival, independent of other prognostic
factors (P¼0.01). Comparison of plasma cytokines between
MDS (n¼78) and primary myeloﬁbrosis (n¼127) revealed
a signiﬁcantly different pattern of abnormalities. These
observations reinforce the concept of distinct and prognos-
tically relevant plasma cytokine signatures in hematological
malignancies.
Leukemia (2012) 26, 693–699; doi:10.1038/leu.2011.251;
published online 13 September 2011
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Introduction
Aberrant cytokine expression accompanies both lymphoid and
myeloid malignancies and is believed to contribute to disease
phenotype and outcome. Recent studies in diffuse large B-cell
lymphoma and primary myeloﬁbrosis (PMF) have provided
proof-of-concept in this regard by demonstrating phenotypic
correlates and a powerful prognostic value for plasma levels of
certain cytokines; circulating levels of interleukin (IL)-2R,
interleukin (IL)-8, IL-12, IL-15 and C–X–C motif chemokine 10
(CXCL10) in PMF and IL-2R, IL-8, IL-10, IL-12, CXCL9 and
CXCL10 in diffuse large B-cell lymphoma were independently
associated with worse survival.
1,2 In addition, in PMF,
JAK2V617F-positive patients, compared to their mutation-
negative counterparts, were more likely to display higher
plasma levels of IL-1RA, IL-2R, IL-6, IL-12, hepatocyte growth
factor (HGF), CXCL10 and monokine induced by interferon
(IFN)-g; other phenotypic correlates included increased levels
of (i) IL-6 and IL-8 with constitutional symptoms, (ii) HGF with
marked splenomegaly, (iii) IL-2R, IL-8, IL-10, macrophage
inﬂammatory protein (MIP)-1a and monocyte chemotactic
protein-1 with red cell transfusion dependency, (iv) IL-2R,
HGF and CXCL10 with leukocytosis and (v) CXCL10 with
thrombocytopenia. Furthermore, a recent report suggested
that anemia response to pomalidomide treatment in PMF was
predicted by lower levels of circulating monocyte chemotactic
protein-1, IL-2R, IL-15 and IL-8.
3
The above-mentioned observations in PMF strongly suggest
that speciﬁc cytokines contribute to speciﬁc disease symptoms
and poor survival, and are also predictive of therapeutic
response. Whether or not the particular nosogenic cytokines
represent the host’s immune response to clonal myeloprolifera-
tion or a tumor-speciﬁc autocrine process is yet to be clariﬁed.
Similarly, the detrimental effect on survival might be mediated
by either exacerbation of co-morbid conditions, such as
cardiovascular disease, or by promoting clonal evolution
and/or leukemic transformation. The latter are consistent with
the general concept of a direct link between inﬂammation and
oncogenesis.
Myelodysplastic syndrome (MDS) and PMF are both clonal
stem cell diseases and share a number of clinical features,
including ineffective erythropoiesis, bone marrow neoangiogen-
esis and an increased risk of leukemic transformation.
These similarities, as well as the known role of immune
dysregulation in MDS development and/or progression,
4,5 led
us to hypothesize that an altered plasma cytokine proﬁle in MDS
is both phenotypically and prognostically relevant and may also
provide additional pathogenetic and therapeutic insights. To
that end, in the current study, we performed a comprehensive
plasma cytokine analysis in 78 patients with primary MDS.
The main objectives of the study were: (i) describe the spectrum
of abnormalities in cytokine levels and their comparison
with normal controls; (ii) identify phenotypic and prognostic
correlates of abnormally expressed cytokines; and (iii) compare
plasma cytokine signatures of MDS and PMF.
Materials and methods
The current study was approved by the Mayo Clinic institutional
review board. All patients provided informed written consent for
study sample collection as well as permission for use in
research. Inclusion to the current study required availability of
archived plasma, bone marrow aspirate and biopsy and
cytogenetic information at the time of ﬁrst referral to the Mayo
Clinic. The diagnoses of MDS and its subclassiﬁcation were
according to the World Health Organization criteria.
6 To assure
mature survival data, follow-up information was updated in
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social security death index or a telephone call to the patient or
their local physician; ‘date of last follow-up’ reﬂected this time
point and not the last time a patient was seen at the Mayo Clinic.
Peripheral blood was collected under a Mayo Clinic protocol
for patients with myeloid malignancies and standard procedures
were followed to centrifuge samples at 41C and store aliquots at
 801C. Concentrations of 30 plasma cytokines were analyzed
in duplicates using Multiplex Bead-based Luminex Technology
(Invitrogen, Carlsbad, CA, USA): IL-1b, IL-1RA, IL-2, IL-2R, IL-4,
IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-16, IL-17,
epidermal growth factor, eotaxin, ﬁbroblast growth factor-basic,
granulocyte–macrophage colony-stimulating factor (GM-CSF),
granulocyte colony-stimulating factor, HGF, IFN-a, IFN-g,
IFN-g-inducible protein 10/CXCL10, monocyte chemotactic
protein-1, monokine induced by IFN-g, MIP-1a, MIP-1b,
regulated on activation normally T-cell expressed and secreted
(RANTES), tumor necrosis factor-a and vascular endothelial
growth factor. Measurements were performed on a Luminex 200
analyzer (Luminex Corporation, Austin, TX, USA) and resulting
data were evaluated using the Xponent software (Luminex
Corporation). The observed intensities of duplicate samples
were averaged and mapped to a ﬁtted curve derived from a
serial dilution series of known cytokine standards; observed
intensities below and above the standard range were marked as
0% and 100%, respectively.
All statistical analyses were considered clinical and laboratory
parameters obtained at the time of ﬁrst referral to the Mayo
Clinic, which usually coincided with the time of plasma
collection for cytokine analysis. Differences in the distribution
of continuous variables between categories were analyzed
by either Mann–Whitney (for comparison of two groups)
or Kruskal–Wallis (comparison of three or more groups) test.
Patient groups with nominal variables were compared by
w
2-test. Overall survival analysis was considered from the date
of ﬁrst referral to the Mayo Clinic (that is, date of plasma
collection) to date of death (uncensored) or last contact
(censored). Date of leukemic transformation replaced date of
death, as the uncensored variable, for estimating leukemia-free
survival. Overall and leukemia-free survival curves were
prepared by the Kaplan–Meier method and compared by the
log-rank test. Cox’s proportional hazard regression model was
used for multivariable analysis. P-values less than 0.05
were considered signiﬁcant. The JMP statistical package
(SAS Institute, Cary, NC, USA) was used for all calculations.
Results
The study population comprised of 78 consecutive patients with
primary MDS (median age, 72 years; range 44–89 years; 67%
male) for whom an archived plasma sample collected at the
time of referral to the Mayo Clinic was available for cytokine
analysis (Table 1). In all, 64 (82%) patients were not receiving
MDS-directed therapy at the time of sample collection, and the
remaining were receiving erythropoiesis-stimulating agents (that
is, recombinant erythropoietin) alone. In total, 57 (73%) patients
were treatment-naı ¨ve; nine (11%) and ﬁve (6%) patients had
previously received hematopoietic growth factors and hypo-
methylating agents, respectively. The International Prognostic
Scoring System (IPSS) distribution was as follows: low (28%),
intermediate-1 (47%), intermediate-2 (18%) and high (5%); the
corresponding distribution per the revised IPSS (IPSS-R) was as
follows: very good 15 (19%), good 33 (43%), intermediate
13 (17%), poor 3 (4%) and very poor 13 (17%). The World
Table 1 Clinical characteristics of 78 patients with de novo MDS
with cytokine proﬁling available at the time of ﬁrst referral at the
Mayo Clinic
Variables All patients with
cytokine proﬁling (n¼78)
Age (years), median (range) 72 (44–89)
Age 465 years, n (%) 61 (78%)
Males (%) 52 (67%)
Hemoglobin (g/dl), median (range) 9.9 (6.9–14.8)
Leukocyte count ( 10
9/l), median (range) 3.4 (1.1–14.9)
Platelet count ( 10
9/l), median (range) 120 (8–817)
IPSS risk group, n (%)
Low 22 (28%)
Intermediate-1 37 (47%)
Intermediate-2 14 (18%)
High 4 (5%)
IPSS-R risk group, n (%)
Very good 15 (19%)
Good 33 (43%)
Intermediate 13 (17%)
Poor 3 (4%)
Very poor 13 (17%)
WHO MDS category, n (%)
RCMD/RCMD-RS 29 (37%)
RAEB-1 13 (17%)
RAEB-2 16 (21%)
RA/RARS 8 (10%)
Isolated del(5q) 7 (9%)
MDS-u 3 (4%)
RCUD (RT) 2 (3%)
BM blasts, n (%)
o5 51 (65%)
5–9 13 (17%)
10–19 14 (18%)
IPSS karyotype, n (%)
Favorable 53 (68%)
Intermediate 13 (17%)
Unfavorable 11 (14%)
IPSS-R karyotype, n (%)
Very good 4 (5%)
Good 53 (69%)
Intermediate 11 (14%)
Poor 1 1 (1%)
Very poor 8 (10%)
Circulating blasts X1%, n (%) 16 (21%)
Hemoglobin o10g/dl, n (%) 43 (55%)
Red cell transfusion requiring, n (%) 40 (51%)
Platelets o100 10
9/l, n (%) 34 (44%)
Treatment at sample date, n (%)
None 64 (82%)
ESA 14 (18%)
Prior MDS treatment, n (%)
None 57 (73%)
Growth factors 9 (11%)
Hypomethylating agents 5 (6%)
Lenalidomide 3 (4%)
Thalidomide 2 (3%)
Other 2 (3%)
Follow-up, months, median (range) 24 (0–114)
Alive, n (%) 32 (41%)
Leukemic transformation, n (%) 6 (7%)
Abbreviations: BM, bone marrow; dl, deciliter; ESA, erythropoiesis-
stimulating agent; g, grams; IPSS, International Prognostic Scoring
System; IPSS-R, Revised International Prognostic Scoring System;
l, liter; MDS, myelodysplastic syndrome; MDS-u, MDS-unclassiﬁed;
n, number; RA, refractory anemia; RAEB, refractory anemia with
excess blasts; RARS, refractory anemia with ringed sideroblasts;
RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS,
refractory cytopenia with multilineage dysplasia and ringed side-
roblasts; RCUD, refractory cytopenia with unilineage dysplasia;
RT, refractory thrombocytopenia; WHO, World Health Organization.
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LeukemiaHealth Organization subgroups were as follows: refractory
cytopenia with multilineage dysplasia/refractory cytopenia with
multilineage dysplasia and ringed sideroblasts: 29 (37%);
refractory anemia with excess blast-1: 13 (17%); refractory
anemia with excess blast-2: 16 (21%); refractory anemia/
refractory anemia with ringed sideroblasts: 8 (10%); MDS with
isolated del(5q): 7 (9%); MDS-unclassiﬁed: 3 (4%); and
refractory cytopenia with unilineage dysplasia (refractory
thrombocytopenia): 2 (3%). Other risk-relevant information,
such as the proportion of patients with red cell transfusion
dependency, unfavorable karyotype and thrombocytopenia, is
outlined in Table 1.
Plasma cytokine levels were measured in 78 patients with
primary MDS (Table 2) and 35 normal controls. Compared to
normal controls, the levels of 19 cytokines were signiﬁcantly
different for MDS patients: all were increased except for
RANTES (Table 2). Phenotypic correlates in MDS included
increased levels of IL-8 with higher IPSS risk category, red cell
transfusion dependency, higher bone marrow blast count and
female gender; increased levels of CXCL10 with the presence of
circulating peripheral blood blasts and thrombocytopenia;
decreased levels of eotaxin with IPSS-deﬁned unfavorable
karyotype; increased levels of RANTES with thrombocytopenia;
and decreased levels of IL-17 with red cell transfusion
dependency; with other associations as outlined in Table 2.
Median follow-up from the time of plasma sample collection
was 24 months (range, 0–114 months); for the 32 living patients,
the median follow-up was 31 months (range, 0–114 months).
During this period, 46 deaths (59%) were documented in this
cohort. A number of clinical and laboratory parameters were
identiﬁed as being associated with shortened survival by using
Cox proportional hazards regression models (Table 3). Of the 18
cytokines that were abnormally elevated in MDS patients, only
three cytokines were associated with shortened survival on
univariate analysis: CXCL10 (Po0.01), IL-6 (P¼0.02) and IL-7
(P¼0.02) (Table 3). All three cytokines maintained their
individual signiﬁcant association with shortened survival when
the Cox model was adjusted for the IPSS or IPSS-R (Table 3).
Consistent with this ﬁnding, there was no signiﬁcant difference
in CXCL-10, IL-7 or IL-6 levels between IPSS low- and high-risk
subgroups, or refractory anemia/refractory anemia with ringed
sideroblasts /isolated (del(5q)/RCUD vs refractory anemia with
excess blast-2 subgroups (P40.05).
On multivariable analysis that included the three cytokines,
increased levels of CXCL10 (Po0.01) and IL-7 (P¼0.02) were
identiﬁed as predictors of shortened survival, whereas
IL-6 maintained borderline signiﬁcance (P¼0.07). The survival
association for CXCL10 (P¼0.02) and IL-7 (P¼0.04)
remained signiﬁcant when the Cox model was adjusted for
IPSS or IPSS-R, age, red cell transfusion dependence and
thrombocytopenia (IL-6 levels remained borderline signiﬁcant
in this analysis).
Based on the strength of their association with survival, a
model for risk categorization of MDS patients based on
increased plasma levels of IL-6, IL-7 and CXCL10 was
developed. For consistency with a previous similar analysis in
PMF patients, a cytokine level that exceeded 3 standard
deviations from the normal mean (43s.d.) was deﬁned as
being signiﬁcantly elevated for the current analysis.
2 MDS
patients with normal plasma levels of IL-6, IL-7 and CXCL10
lived signiﬁcantly longer (n¼20; median survival 76 months) as
compared to those with increased levels of one or more of the
three cytokines (n¼57; median survival 25 months) (Po0.01)
(Figure 1). The risk-categorization model retained its predictive
signiﬁcance when adjusted for IPSS (or IPSS-R), red cell
transfusion dependence and thrombocytopenia using a Cox
Table 2 Cytokines whose plasma levels are abnormally increased (or decreased) in 78 patients with de novo MDS and their relationship with
age, gender and clinically relevant disease features at the time of ﬁrst referral at the Mayo Clinic
Cytokines
(pg/ml)
Controls
median
(range),
n¼35
MDS
patients
median
(range),
n¼78
P-value Age
465
years
Female
gender
WHO
MDS
category
IPSS
category
RBC
transfusion
depen-
dency
IPSS
karyotype
category
BM
blasts
category
PB
blasts
X1%
Hemo-
globin
o10 g/dl
Platelets
o100 
10
9/l
IL-1RA 203 (2–419) 240 (0–13171) 0.02 NS NS NS NS NS NS NS NS 0.06 NS
IL-4 7.2 (0–33) 41 (0–5549) 0.04 NS NS NS NS NS NS NS NS NS NS
IL-6 0.6 (0–9.1) 4.6 (0–236) 0.0007 NS NS NS NS NS NS NS NS NS NS
IL-7 7.6 (0–52) 0 (0–105) 0.03 NS NS NS NS NS NS NS NS NS NS
IL-8 3.3 (0–18) 17 (0–714) o0.0001 NS 0.03 0.02 0.01 0.007 NS 0.02 NS NS NS
IL-13 0 (0–0) 59 (0–97) o0.0001 NS NS NS NS NS NS NS NS NS NS
IL-15 0 (0–38) 24 (0–5324) o0.0001 NS NS NS NS NS NS NS NS NS NS
IL-17 0 (0–15) 0.7 (0–2844) 0.03 NS NS NS NS 0.05
* NS NS NS NS 0.09
TNF-a 0 (0–15) 3 (0–287) o0.0001 NS NS 0.04 NS NS NS NS NS NS NS
G-CSF 33 (0–373) 145 (0–1388) o0.0001 NS NS NS NS NS NS NS NS NS NS
IFN-g 5.5 (0–23) 22.2 (0–139.1) o0.0001 NS NS NS NS NS NS NS NS NS NS
MIP-1b 21.8 (4.4–91) 41 (0–1415) 0.04 NS NS NS NS NS NS NS NS NS NS
HGF 129 (0–433) 240 (0–2313) o0.0001 NS NS NS NS NS NS NS NS NS NS
CXCL10 22 (4–97) 107 (0–1414) o0.0001 NS NS 0.09 0.08 NS NS NS 0.02 NS 0.02
MIG 19.4 (0–86) 72.4 (0–1473) o0.0001 NS NS NS NS NS NS NS NS NS NS
Eotaxin 47.5 (7.6–155.5) 60.9 (2.2–690) 0.02 NS NS NS NS NS 0.02
* NS NS NS NS
RANTES 4130 (0–34347) 59.5 (0–18294) 0.0005 NS NS NS NS NS NS NS NS 0.08 0.006
MCP-1 173 (61–342) 247 (0–4306) 0.002 0.03 NS NS NS NS NS NS NS NS NS
VEGF 1 (0–2.7) 3.4 (0–40.5) 0.009 NS NS NS NS NS NS NS NS NS 0.09
Abbreviations: BM, bone marrow; CXCL10, C–X–C motif chemokine 10; dl, deciliter; IFN, interferon; IL, interleukin; IPSS, International Prognostic
Scoring System; g, grams; G-CSF, granulocyte colony-stimulating factor; HGF, hepatocyte growth factor; l, liter; MCP-1, monocyte chemotactic
protein-1; MDS, myelodysplastic syndrome; MIG, monokine induced by IFN-g; MIP, macrophage inﬂammatory protein; ml, milliliter; n, number;
NS, not signiﬁcant (P40.05); PB, peripheral blood; pg, picogram; RANTES, regulated on activation normally T-cell expressed and secreted;
RBC, red blood cell; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor; WHO, World Health Organization.
Disease-relevant characteristics signiﬁcantly associated with increased cytokine levels, except as indicated by asterisk (*).
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Leukemiaproportional hazards regression model (P¼0.03; Risk
ratio¼2.7, 95% conﬁdence interval¼1.1–8.2).
In the present cohort, complete follow-up information (up to
June 2011) including cause of death (where applicable) was
available for 50 MDS patients (64%); of these, six patients (12%)
were conﬁrmed to have undergone leukemic transformation.
Leukemia-free survival was signiﬁcantly associated with
increased IL-6 level (P¼0.01) and borderline associated with
increased CXCL10 level (P¼0.09), but not with increased IL-7
level (P¼0.8). The association between inferior leukemia-free
survival and increased IL-6 was not accounted for by age,
transfusion dependence, IPSS, IPSS-R, World Health Organiza-
tion MDS category, thrombocytopenia, IPSS-deﬁned karyotype
or BM blast category (Po0.05). The present ﬁndings were not
affected when the analysis was extended to the entire cohort;
that is, the remaining 28 MDS patients were included after
censoring for leukemic transformation at the date of last follow-
up (data not shown).
Given recent data regarding a similar signiﬁcant association of
cytokines with speciﬁc phenotypic features as well as clinical
outcome (overall and leukemia-free survival) in PMF,
2 we
sought to compare plasma cytokine levels between the two
diseases (that is, MDS and PMF). Of the 31 cytokines
interrogated, plasma levels of all except IL-2, IL-5, IL-8,
granulocyte–macrophage colony-stimulating factor, monocyte
chemotactic protein-1 and vascular endothelial growth factor
were signiﬁcantly different between the two disease groups
(Table 4).
Discussion
The MDS are a clinically and molecularly heterogeneous group
of clonal hematopoietic stem cell disorders that are singularly
characterized by peripheral blood cytopenias from ineffective
hematopoiesis and an increased but variable risk of leukemic
transformation.
7 Dysregulation of the immune system is thought
to play an important role in MDS pathogenesis by promoting the
development and/or progression of disease. The best evidence in
this regard comes from the proven efﬁcacy of immunosuppres-
sive therapies such as anti-thymocyte globulin, cyclosporin A
and alemtuzumab in at least a subset of MDS patients where
autoimmunity is the central pathophysiological mechanism,
8–11
and also the frequent concurrence of autoimmune conditions
with MDS.
12 Further evidence comes from a large, population-
based, case–control study using registry data, which demon-
strated that chronic immune stimulation, represented by a wide
range of infectious or autoimmune conditions, was signiﬁcantly
associated with an increased risk of developing MDS or acute
myeloid leukemia.
13
Various aspects of immune dysregulation have been studied
in MDS, including the antigen-driven expansion of autoreactive
CD8þ T cells of restricted Vb repertoire that are capable of
suppressing hematopoietic colony growth in vitro.
14,15 Evidence
for impaired immune surveillance comes from the presence of
dysfunctional natural killer (NK) cells with decreased cytolytic
activity possibly reﬂecting expansion of clonal NK cells and/or
decreased expression of NK activating receptors,
16,17 and also
from the presence of increased numbers of peripheral blood
Table 3 Overall survival using Cox proportional hazards model
(univariate analysis)
Variable P-value Risk ratio
(95% CI)
Age (years) 0.04
Hemoglobin (g/dl) 0.02
RBC transfusion dependency 0.006 2.3 (1.3–4.2)
Platelet count o100 100
9/l 0.06 1.8 (0.97–3.2)
IPSS category 0.004
IPSS-R category 0.2
WHO MDS category 0.002
RAEB vs RA/RARS/del(5q)/RCUD 0.0006 4.2 (1.8–11.2)
RAEB vs RCMD/RCMD-RS 0.01 2.3 (1.2–4.6)
RCMD/RCMD-RS vs RA/RARS/
del(5q)/RCUD
0.2 187 (0.8–4.8)
Presence of circulating blasts 0.01 2.5 (1.2–4.6)
BM blast category (o5% vs X5%) 0.005 2.5 (1.3–4.6)
IL-6 level (continuous)
Unadjusted 0.02
Adjusted for IPSS 0.04
Adjusted for IPSS-R 0.04
CXCL10 level (continuous)
Unadjusted 0.002
Adjusted for IPSS 0.01
Adjusted for IPSS-R 0.02
IL-7 level (continuous)
Unadjusted 0.02
Adjusted for IPSS 0.01
Adjusted for IPSS-R 0.03
Abbreviation: CI, conﬁdence interval; CXCL10, C–X–C motif chemo-
kine 10; dl, deciliter; g, grams; IL, interleukin; IPSS, International
Prognostic Scoring System; IPSS-R, Revised International Prognostic
Scoring System; l, liter; MDS, myelodysplastic syndrome; RA,
refractory anemia; RAEB, refractory anemia with excess blasts; RARS,
refractory anemia with ringed sideroblasts; RBC, red blood cell;
RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS,
refractory cytopenia with multilineage dysplasia and ringed side-
roblasts; RCUD, Refractory cytopenia with unilineage dysplasia;
WHO, World Health Organization.
Figure 1 Survival data for 78 patients with primary MDS stratiﬁed
based on plasma levels of CXCL10, IL-7 and IL-6: (i) normal levels of
all three cytokines (red curve) or (ii) increased (43 standard deviations
of the normal mean level) level(s) of one or more of the aforemen-
tioned cytokines (blue curve). MDS patients with increased cytokine
level(s) had a signiﬁcantly inferior survival (n¼57; median
survival¼25 months) as compared to those with normal levels of all
three cytokines (n¼20; median survival approximately 76 months)
(log-rank P-value¼0.002). This association with inferior overall
survival was sustained on multivariate analysis.
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LeukemiaT regulatory cells (deﬁned as CD4þ, CD25
high Foxp3þ T cells)
of polyclonal origin, particularly in advanced MDS patients.
18,19
Another possible mechanism is the inﬂammatory cytokine-
driven expansion of myeloid-derived suppressor cells that
may further contribute to the development of immune tolerance
in MDS.
5
MDS patients exhibit an abnormal cytokine milieu that likely
stems from the interaction of the MDS clone with bone marrow
stromal cells and inﬁltrating immune effector cells that under-
pins the persistent low-level inﬂammatory state. Although much
of the attention has been focused on the study of individual
myelosuppressive/pro-apoptotic or pro-inﬂammatory cytokines
such as tumor necrosis factor-a, tumor growth factor-b, IFN-g or
IL-6,
20–26 only two previous studies to our knowledge have
attempted to comprehensively proﬁle circulating cytokine–
chemokine levels in MDS patients.
27,28 In one study of 162
acute myeloid leukemia and 100 MDS patients who proﬁled 27
cytokines, a combined analysis of both patient groups showed
that serum (not plasma) levels of CSF3, IL-1RA, IL-8, IL-12,
IL-15, CXCL10, tumor necrosis factor -a and IL-17 were
signiﬁcantly elevated relative to normal controls.
27 Unexpect-
edly, the expression proﬁles of 24 of the 27 cytokines were
statistically indistinguishable between acute myeloid leukemia
and MDS patients. Although individual cytokine levels were not
correlated with clinical or laboratory features, elevated levels of
IL-4 and MIP-1a were associated with longer survival in MDS;
the latter observation was however not conﬁrmed within
the context of other known prognostic factors in MDS in a
multivariate analysis. In the other study of 33 aplastic anemia
and 57 MDS patients, plasma levels of tumor necrosis factor -a,
IL-6, MIP-1a, MIP-1b and HGF were increased in MDS relative
to aplastic anemia or normal controls.
28 Although distinct
cytokine signature proﬁles were identiﬁed for AA and MDS
patients, there were no data presented regarding clinical or
laboratory correlates of individual cytokines or any information
regarding association of cytokine levels with clinical outcome.
The current study adds signiﬁcant novel information relative
to the two aforementioned studies of cytokine proﬁling in MDS.
First, we measured cytokine levels in plasma, which may be an
advantage given the signiﬁcant differences in levels of soluble
protein factors between plasma relative to serum due to
activation of the coagulation cascade in the latter. Second, the
vast majority of MDS patients in our study were not receiving
active therapy at the time of sample collection and none were
receiving disease-modifying therapy that could potentially alter
the disease-inherent baseline cytokine proﬁle. Third, the follow-
up of patients in our cohort was mature, thereby allowing for full
analysis of the effect of cytokine levels on overall survival and
leukemia-free survival. Fourth, availability of a fully annotated
clinical database allowed a detailed assessment of association of
cytokine levels with clinical or laboratory features. Fifth,
updated prognostic information per the IPSS-R was incorporated
and the added prognostic impact of cytokine levels on clinical
outcome was conﬁrmed within this context. Sixth, a full
comparison of cytokine proﬁles between MDS and PMF was
conducted given the disease similarities in terms of anemia
Table 4 Comparison of plasma cytokine levels between 78 patients with de novo MDS and 127 patients with primary myeloﬁbrosis
Cytokines (pg/ml) Controls median
(range), n¼35
MDS patients median
(range), n¼78
PMF patients median
(range), n¼127
P-value
IL-1b 4 (0–49) 4.8 (0–1858) 10.8 (0–3576) 0.03
IL-1RA 203 (2–419) 240 (0–13171) 552 (37–9991) o0.0001
IL-2 6.1 (0–28) 7.5 (0–2554) 5.1 (0–1562) NS
IL-2R 217 (0–507) 236 (0–11027) 556 (91–3956) o0.0001
IL-4 7.2 (0–33) 41 (0–5549) 6.4 (0–580) 0.01
EGF 32.7 (0–356) 17.7 (0–1611) 31.7 (0–3186) 0.003
IL-5 0 (0–8) 1.9 (0–7.4) 0 (0–3998) NS
IL-6 0.6 (0–9.1) 4.6 (0–236) 6.3 (0–186) 0.03
IL-7 7.6 (0–52) 0 (0–105) 7.5 (0–475) 0.0001
IL-8 3.3 (0–18) 17 (0–714) 14.3 (0–1156) NS
IL-10 4.8 (2.3–51) 10.3 (0–46) 12.5 (2–2009) o0.0001
FGF-b 16 (0–67) 18.9 (0–1805) 25.1 (0–861) 0.04
IL-12 100 (35–182) 95 (0–2960) 192 (18–1883) o0.0001
IL-13 0 (0–0) 59 (0–97) 0 (0–4909) 0.001
IL-15 0 (0–38) 24 (0–5324) 0 (0–2671) o0.0001
IL-17 0 (0–15) 0.7 (0–2844) 0 (0–425) 0.0004
TNF-a 0 (0–15) 3 (0–287) 0 (0–400) o0.0001
G-CSF 33 (0–373) 145 (0–1388) 45 (0–888) 0.0002
IFN-a 27.6 (0–96) 16 (0–1463) 42 (0–1021) 0.001
IFN-g 5.5 (0–23) 22.2 (0–139.1) 42 (0–1021) 0.0001
GM-CSF 0 (0–172) 0 (0–261) 0 (0–2950) NS
MIP-1a 0 (0–112) 0 (0–2139) 25.4 (0–1305) o0.0001
MIP-1b 21.8 (4.4–91) 41 (0–1415) 65.7 (0–1935) o0.0001
HGF 129 (0–433) 240 (0–2313) 391 (0–11572) o0.0001
CXCL10 22 (4–97) 107 (0–1414) 72 (5.3–755) 0.0008
MIG 19.4 (0–86) 72.4 (0–1473) 49 (0–971) 0.0009
EOTAXIN 47.5 (7.6–156) 60.9 (2.2–690) 40.2 (5.4–274) o0.0001
RANTES 4130 (0–34347) 59.5 (0–18294) 4881 (0–801880) o0.0001
MCP-1 173 (61–342) 247 (0–4306) 222 (62–1705) NS
VEGF 1 (0–2.7) 3.4 (0–40.5) 2.3 (0–47) NS
Abbreviations: CXCL10, C–X–C motif chemokine 10; FGF-b, ﬁbroblast growth factor-basic; G-CSF, granulocyte colony-stimulating factor;
GM-CSF, granulocyte–macrophage colony-stimulating factor; HGF, hepatocyte growth factor; IFN-g, interferon-g; IL, interleukin; MCP-1, monocyte
chemotactic protein-1; MDS, myelodysplastic syndrome; MIG, monokine induced by IFN-g; MIP, macrophage inﬂammatory protein; n, number;
NS, not signiﬁcant (P40.05); pg, picogram; PMF, primary myeloﬁbrosis; TNF, tumor necrosis factor; RANTES, regulated on activation normally T-
cell expressed and secreted; VEGF, vascular endothelial growth factor.
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Leukemiaprevalence, presence of constitutional symptoms and increased
risk of bone marrow failure and leukemic transformation.
In the current study of MDS patients, IL-8 and CXCL10 stand
out as the most relevant cytokines in terms of phenotypic
correlations and CXCL10, IL-7 and IL-6 in terms of their
prognostic impact. Shortened overall survival was predicted by
increased levels of the latter three cytokines independent of
conventional prognostic factors in MDS that included IPSS
or IPSS-R,
29,30 age,
31,32 red cell transfusion dependence
33,34
and thrombocytopenia.
31,32 This suggests a signiﬁcant pathoge-
netic contribution of the aforementioned cytokines in disease
development and/or progression that is independent of the MDS
clone and conﬁrms the importance of dysregulated immunity in
MDS. Accordingly, the cytokine data could be effectively
combined into a model for risk categorization, wherein normal
levels of all three cytokines identiﬁed MDS patients with
signiﬁcantly longer survival relative to those with elevated
levels of one or more cytokines. Although the predictive value of
this model was conﬁrmed to be independent of known
prognostic factors in MDS for the overall cohort, the analysis
was not extended to IPSS subsets given the limited number
of patients in the current study.
Death in MDS patients results from the competing phenom-
ena of worsening co-morbidities, bone marrow failure and
leukemic transformation. In an analysis of the association of
speciﬁc cytokines with the risk of leukemic transformation, we
found that two of the three cytokines that were associated with
inferior overall survival (IL-6, and to a lesser extent CXCL10)
were also predictive for inferior leukemia-free survival in MDS,
independent of previously established prognostic factors in this
regard. This observation suggests an additional permissive role
of speciﬁc cytokines in the process of clonal evolution in MDS
and identiﬁes at least one reason for the inferior survival of
patients with increased cytokine levels. Additional studies are
needed to ascertain whether elevated cytokine levels are also
implicated in excess deaths due to increased progression
of co-morbidities such as cardiovascular disease, and so on.
Observations from the current study reinforce the concept of
distinct and prognostically relevant plasma cytokine signatures
in hematological malignancies. Although the plasma cytokine
proﬁle between MDS and PMF is substantially dissimilar, it is
interesting to note that CXCL10 was identiﬁed as an indepen-
dent prognostic indicator in both diseases and also large-cell
lymphoma.
1,2 The particular observation suggests a general host
response to a disease state with an aggressive biology rather than
a tumor-speciﬁc cytokine release. Also of note is the observation
that the other prognostically relevant cytokines were different
between MDS (IL-6, IL-7) and PMF (IL-2R, IL-8, IL-12, IL-15) or
large-cell lymphoma (IL-2R, IL-8, IL-10, IL-12, CXCL9). In this
instance, some of the nosogenic cytokines might be under the
control of a tumor-speciﬁc autocrine process and therefore also
relevant to disease pathogenesis. With regards to MDS-relevant
cytokines, IL-7 was initially identiﬁed as a growth factor for
B-lymphocyte progenitors and is now known to be an important
regulator for many aspects of B-cell lymphopoiesis.
35 IL-6 is a
pro-inﬂammatory cytokine, which has an important role in
activating the immune system, particularly in the transition
from an innate to an acquired immune response.
36 CXCL10 is a
chemokine induced by IFN-g, and is also classiﬁed as an
inﬂammatory cytokine; this chemokine binds to CXCR3 and
regulates the immune response through the activation and
recruitment of various immune-competent cells.
37
The observations from the current study may also have
therapeutic implications, an aspect that is exempliﬁed by the
known activity of drugs such as thalidomide and lenalidomide
that have broad immunomodulatory activity in MDS.
38 Patients
with MDS face not only shortened survival, but also a major
compromise in quality of life as a result of frequent red blood
cell transfusion requirement and other complications such as
infections and bleeding. It is possible that the speciﬁc
aforementioned cytokines or their downstream signaling inter-
mediates can be therapeutically targeted to alleviate clinically
relevant aspects of MDS.
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